Shares in TiGenix jump after stem cell therapy hits PhIII endpoint

On a day when stock markets tumbled, TiGenix (EBR:TIG) saw its share price jump by more than 20% on the strength of data it thinks represents the first time an allogeneic stem cell therapy has aced Phase III. And having hit the primary endpoint in the …

[Read the full article here]

Comments are closed.